Artificial Neural Processing-Driven Bioelectronic Nose for the Diagnosis of Diabetes and Its Complications

Adv Healthc Mater. 2023 Oct;12(26):e2300845. doi: 10.1002/adhm.202300845. Epub 2023 Aug 4.

Abstract

Diabetes and its complications affect the younger population and are associated with a high mortality rate; however, early diagnosis can contribute to the selection of appropriate treatment regimens that can reduce mortality. Although diabetes diagnosis via exhaled breath has great potential for early diagnosis, research on such diagnosis is restricted to disease detection, requiring in-depth examination to diagnose and classify diseases and their complications. This study demonstrates the use of an artificial neural processing-based bioelectronic nose to accurately diagnose diabetes and classify diabetic types (type I and II) and their complications, such as heart disease. Specifically, an M13 phage-based electronic nose (e-nose) is used to explore the features of subjects with diabetes at various levels of cellular and organismal organization (cells, liver organoids, and mice). Exhaled breath samples are collected during culturing and exposed to the phage-based e-nose. Compared with cells, liver organoids cultured under conditions mimicking a diabetic environment display properties that closely resemble the characteristics of diabetic mice. Using neural pattern separation, the M13 phage-based e-nose achieves a classification success rate of over 86% for four conditions in mice, namely, type 1 diabetes, type 2 diabetes, diabetic cardiomyopathy, and cardiomyopathy.

Keywords: bioelectronic noses; cellular respiration; diabetes diagnosis; m13 bacteriophage; neural processing.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Breath Tests
  • Diabetes Mellitus, Experimental* / diagnosis
  • Diabetes Mellitus, Type 1*
  • Diabetes Mellitus, Type 2*
  • Electronic Nose
  • Exhalation
  • Humans
  • Mice